Astellas Acquires Fezolinetant for Menopausal Symptoms in Ogeda Acquisition

By Natasha Piper

Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)

Published: 20 Apr-2017

DOI: 10.3833/pdr.v2017.i4.2239     ISSN: 1756-7874

Section: Mergers & Acquisitions

Fulltext:

Abstract

Astellas has agreed to acquire Ogeda thereby gaining a Phase II drug, fezolinetant, for the treatment of hot flushes related to menopause in a deal worth €800 M (US$853 M)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details